Eli Lilly has entered a significant collaboration with Superluminal Medicines in a deal potentially worth $1.3 billion, including upfront payments, equity investments, development and commercial milestones, plus royalties. The partnership focuses on developing novel therapeutics aimed at cardiometabolic diseases and obesity via undisclosed G protein-coupled receptor targets. Lilly also announced plans to raise drug prices in Europe to lower U.S. prices, aligning with policy initiatives addressing international pricing disparities.